Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided AI claim is directly supported by the supplied FDA labeling excerpts (Section 5.1: Serious Infections), including serious/sometimes fatal infections, opportunistic infections (e.g., TB, invasive fungal), avoidance in active serious infection, monitoring, and interrupting therapy when serious/opportunistic infection or sepsis occurs.
Category Scores
Accurate Statements
Tofacitinib is associated with increased risks of serious and sometimes fatal infections.
Supported by Section 5.1 (Serious Infections): “Serious and sometimes fatal infections may occur with tofacitinib.”
Opportunistic infections are included, such as TB and invasive fungal infections.
Supported by Section 5.1 listing opportunistic infections including “tuberculosis and other mycobacterial infections” and invasive fungal infections (e.g., “cryptococcosis,” “histoplasmosis,” “esophageal candidiasis,” “pneumocystosis”).
The label advises avoiding use in patients with an active, serious infection.
Supported by Section 5.1: “Avoid use of tofacitinib in patients with an active, serious infection, including localized infections.”
The label advises monitoring closely and interrupting tofacitinib if serious infection, opportunistic infection, or sepsis occurs.
Supported by Section 5.1: “Closely monitor patients…” and “Interrupt tofacitinib if a patient develops a serious infection, an opportunistic infection, or sepsis.”
The label includes TB evaluation/testing prior to and during tofacitinib administration (per applicable guidelines).
Supported by Section 5.1: “Evaluate and test patients for latent or active tuberculosis (TB) infection prior to and per applicable guidelines during administration…”
Unsupported Statements
Contradictions
Important Omissions
The AI response did not address other labeled risks present in the provided excerpts (increased risk of mortality, malignancy/lymphoproliferative disorders, major adverse cardiovascular events, thrombosis) because the claim was limited to serious infections.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements correctly reflect labeled infection warnings and associated management steps (avoid active serious infection, monitor, interrupt therapy, and TB evaluation/testing).
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement
If expanding beyond infections, include other labeled boxed/warning topics shown in the provided excerpts (mortality, malignancy, MACE, thrombosis) to fully cover the safety profile.